Nanchang Peoples hospital
Nanchang 330200
7 studies enrolling now · 10 studies all time
What they study most
Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Breast Cancer, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Elevated Lp(a), HER2-positive Breast Cancer, Heart Failure, Hypertension, Lipoprotein Disorder, Metastatic Breast Cancer, Obesity
Studies at this site
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive — Recruiting now
- Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) — Recruiting now
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
- Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling